Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Lilly adds to obesity drug production push with $3B investment
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health system over the next three years.
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible, and alongside a specialized diet.
Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly to Boost Obesity Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its blockbuster diabetes and weight-loss drugs.
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments
Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.
Lilly planning $3B expansion of Wisconsin plant to boost production
Eli Lilly (NYSE:LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its recently acquired manufacturing facility in Kenosha County, Wisconsin. Lilly expects to start construction on the expansion in 2025,
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd ...
STAT1d
Pharmalittle: We’re reading about U.K. restricting Lilly’s obesity drug, pharma layoffs, and more
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
FiercePharma2d
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
Healthy Returns: Wall Street mulls over Amgen's weight loss drug data
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
BioPharma Dive2d
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
Altimmune CEO on what’s next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...